87270
document
[ Effectiveness of adjuvant hormone therapy in breast cancer ] . A third series of randomized tests was undertaken to evaluate the efficacy of postoperative adjuvant hormone therapy ( tamoxifen , diethylstilbestrol , orimethen amino glutethymide ) in breast cancer patients . Tamoxifen was studied in 176 patients with T1-2N0M0 tumors . Five-year recurrence-free survival was registered in 85.2 % of menopausal patients treated with tamoxifen versus 71.1 % in control ( P < 0.05 ) . Five-year recurrence-free survival in menopausal females with breast tumors , stage IIb , was 71.1 % among those treated with diethylstilbestrol and as low as 57.4 % in the tamoxifen group ( P < 0.05 ) . Untoward side-effect incidence was much higher in the diethylstilbestrol group ( 30.4 % ) as compared with tamoxifen ( 3.5 % ) . No significant difference was found for the relationship between orimethen and tamoxifen treatment with respect to 5-year survival and recurrence-free survival .
87271
Intervention_Pharmacological
adjuvant hormone therapy
87272
Intervention_Pharmacological
adjuvant hormone therapy
87273
Intervention_Pharmacological
tamoxifen
87274
Intervention_Pharmacological
diethylstilbestrol
87275
Intervention_Pharmacological
orimethen amino glutethymide
87276
Intervention_Pharmacological
Tamoxifen
87277
Intervention_Pharmacological
tamoxifen
87278
Intervention_Pharmacological
tamoxifen
87279
Intervention_Pharmacological
tamoxifen
87280
Intervention_Pharmacological
orimethen
87281
Intervention_Pharmacological
tamoxifen
87282
Outcome_Other
evaluate
87283
Outcome_Physical
efficacy
87284
Outcome_Mortality
Five-year recurrence-free survival
87285
Outcome_Mortality
Five-year recurrence-free survival
87286
Outcome_Adverse-effects
Untoward side-effect incidence
87287
Outcome_Physical
much higher
87288
Outcome_Mortality
5-year survival and recurrence-free survival .
87289
Participant_Condition
breast cancer
87290
Participant_Sample-size
176
87291
Participant_Condition
patients with T1-2N0M0 tumors .